TRVI Projected Dividend Yield
Trevi Therapeutics Inc ( NASDAQ : TRVI )Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) to treat neurologically mediated conditions. Co. is developing Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Haduvio is an oral extended-release formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and m-opioid receptor antagonist. 20 YEAR PERFORMANCE RESULTS |
TRVI Dividend History Detail TRVI Dividend News TRVI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |